US 7812150
RNAi modulation of Aha and therapeutic uses thereof
granted A61PA61P1/18A61P11/00
Quick answer
US patent 7812150 (RNAi modulation of Aha and therapeutic uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Oct 07 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Oct 12 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 07 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61P, A61P1/18, A61P11/00, A61P35/00, A61P35/02